Disease-modifying therapy in adult relapsing-remitting multiple sclerosis

Formulary

Volumn 45, Issue 8, 2010, Pages 252-262

  Rosenzweig, Tamara M ^a   Hartman, Sarah ^a,b   MacKenzie, Elizabeth ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; ALEMTUZUMAB; BETA1A INTERFERON; CLADRIBINE; CORTICOSTEROID; DACLIZUMAB; DALFAMPRIDINE; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; LAQUINIMOD; METHYLPREDNISOLONE; MITOXANTRONE; MONOCLONAL ANTIBODY; NATALIZUMAB; NEUTRALIZING ANTIBODY; RITUXIMAB; TERIFLUNOMIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACNE; ADULT; ALOPECIA; ANXIETY; AUTOIMMUNE DISEASE; BRADYCARDIA; CARDIOTOXICITY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL PRACTICE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DEGENERATIVE DISEASE; DEPRESSION; DISABILITY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DRUG APPROVAL; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; EVIDENCE BASED MEDICINE; EVOKED VISUAL RESPONSE; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FLU LIKE SYNDROME; FLUSHING; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEALTH ECONOMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HERPES ZOSTER; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOTHERAPY; INCREASED APPETITE; INFECTION; INJECTION SITE REACTION; INSOMNIA; LEG MUSCLE; LEUKOPENIA; LIVER FUNCTION TEST; LIVER INJURY; LUNG FUNCTION; LYMPHOCYTOPENIA; META ANALYSIS; MONOTHERAPY; MULTIPLE SCLEROSIS; MUSCLE STRENGTH; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PATHOPHYSIOLOGY; PATIENT MOBILITY; PATIENT MONITORING; PERIPHERAL EDEMA; PHARYNGITIS; PLASMAPHERESIS; PRACTICE GUIDELINE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSYCHOSIS; RECOMMENDED DRUG DOSE; RELAPSE; REMISSION; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; SINUS CONGESTION; SUSTAINED RELEASE FORMULATION; THROMBOCYTOPENIC PURPURA; THYROID DISEASE; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE COLOR; WALKING SPEED;

EID: 77958479714     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Castelli-Haley J, Lage MJ, Oleen-Burkey MKA, Johnson KP. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients. Adv Ther. 2008;25(7):658-673.
2. Rizvi SA, Agius MA. Current approved options for treating patients with multiple sclerosis. Neurology. 2004;63(suppl 6):S8-S14.
3. Courtney AM, Treadaway K, Remington G, Frohman E. Multiple sclerosis. Med Clin NAm. 2009;93:451-476.
4. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343(13):938-952.
5. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2):169-178.
6. Galetta SL, Markowitz C, Lee AG. Immu-nomodulatory agents for the treatment of relapsing multiple sclerosis. Arch Intern Med. 2002;62:2161-2169.
7. National Institute for Clinical Excellence (NICE). Multiple sclerosis: national clinical guideline for diagnosis and management in primary and secondary care. 2004. Available at: http://www.rcplondon.ac.uk/pubs/books/ms/. Accessed July 29, 2010.
8. Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC. Assessment: the use of natali-zumab ( Tysabri) for the treatment of multiple sclerosis (an evidence based review). Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;71:766-773.
9. National Clinical Advisory Board of the National Multiple Sclerosis Society. MS Disease Management Consensus Statement. 2007. Modified February 2, 2010. Available at: www.nationalmssociety.org/download.aspx?id=8. Accessed July 29, 2010.
10. McDonald WI, Compston A, Edan G, et al. Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol. 2001;50:121-127.
11. Polman CH, Reingold SC, Edan G, et al. Diagnostic Criteria for Multiple Sclerosis: 2005 Revisions to the "McDonald Criteria." Ann Neurol. 2005;58:840-846.
12. Leary SM, Porter B, Thompson AJ. Multiple Sclerosis: diagnosis and the management of acute relapses. Postgrad Med J. 2005; 81:302-308.
13. Sellebjerg F, Barnes D, Filippini G, et al. EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol. 2005;12 (12):939-946.
14. Martinez-Caceres EM, Barrau MA, Brieva L, Montalban X. Treatment with methylpredniso-lone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects. Clin Exp Immnol. 2002;127:165-171.
15. Avonex [package insert]. Cambridge, MA: Biogen Idec, Inc; 2006.
16. Rebif [package insert]. New York, NY: Pfizer, Inc; 2008.
17. Betaseron [ package insert]. Montville, NJ: Bayer Healthcare Pharmaceuticals; 2007.
18. Copaxone [package insert]. Kansas City, MO: Teva Pharmaceutical Industries, LLC; 2007.
19. Novantrone [package insert]. Rockland, MA: Serono, Inc; 2008.
20. Tysabri [package insert]. Cambridge, MA: Bio-gen Idec, Inc; 2008.
21. National Institute for Clinical Excellence (NICE): Beta Interferon and glatiramer acetate for the treatment of multiple sclerosis. 2002. Available at: http://www.nice.org.uk/niceme-dia/live/11441/32290/32290.pdf. Accessed July 29, 2010.
22. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology.1993; 43 (4): 655-661.
23. The UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45(7):1277-1285.
24. Carmona O, Sasado V, Moral E, et al. Interferon-β1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response. Eur Neurol. 2008; 60:278-284.
25. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996; 39(3):285-294.
26. Coppola G, Lanzillo R, Florio C, et al. Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis. Eur J Neurol. 2006;13:1014-1021.
27. PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancer. 1998;352:1498-1504.
28. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology. 2006;67:944-953.
29. Melo A, Rodrigues B, Bar-Or A. Beta interferons in clinically isolated syndromes. Arq Neurop-siquiarr.2008;66(1):8-10.
30. Durelli L, Verdun E, Barbero P, et al. Every-oth-er-day interferon beta-1b versus once weekly in-terferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicenter study (INCOMIN). Lancet. 2002;359:1453-1460.
31. Panitch H, Goodin D, Francis G, et al. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: fnal comparative results of the EVIDENCE trial. J Neurol Sci. 2005;239:67-74.
32. Traboulsee A, Sabbagh AL, Bennett R, et al. Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-re-mitting sclerosis: analysis of 48-week data from the EVIDENCE (evidence of interferon dose-response: European North American comparative efficacy) study. BMC Neurol. 2008;8:11.
33. Boneschi F, Rovaris M, Johnson KP, et al. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Mult Scler. 2003;9:349-355.
34. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glat-iramer acetate in patients with relapsing multiple sclerosis (the Rebif vs Glatiramer Acetate in Relapsing MS Disease [REGARD Study). Lancet Neurol. 2008;7:903-914.
35. Haas J, Firzlaff M. Twenty-four-month comparison of immunomodulatory treatments-a retro-spective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neurol. 2005;12:425-431.
36. Fox EJ. Mechanism of action of mitoxantrone. Neurology. 2004;63(suppl 6):S15-S18.
37. Cohen BA, Mikol DD. Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology. 2004;63(suppl 6):S28-S32.
38. National Institutes of Health. ClinicalTrials. gov. Available at: http://www.clinicaltrials.gov/ ct2/show/NCT00262314?term=renew&rank=2. Accessed July 27, 2010.
39. Martinelli BF, Rovaris M, Capra R, et al. Mitoxantrone for multiple sclerosis. Cochrane Database of Systematic Reviews. 2005; Issue 4. Art.No.:CD002127.DOI:10.1002/14651858. CD002127.pub2.
40. Thomson Reuters. Biogen reports six new PML cases with Tysabri: correction. Reuters. Available at: http://www.reuters.com/article/ idUSN1725307720100617. Updated June 17, 2010. Accessed July 29, 2010.
41. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natali-zumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899-910.
42. Rudick RA, Stuart WH, Calabresi PA, et al. Na-talizumab plus interferon beta-1a for relapsing multiple sclerosis. NEngl J Med. 2006;354:911-923.
43. Goodman AD, Rossman H, Bar-Or A, et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology. 2009;72:806-812.
44. Goodman AD, Brown TR, Krupp LB. Fam-pridine MS-F203 Study Group. Sustained-release oral fampridine in multiple sclerosis: a randomized, double-blind, controlled trial. Lancet. 2009;373:732-738.
45. Multiple Sclerosis Therapy Consensus Group (MSTCG). Basic and escalating immuno-modulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neu-rol. 2008;255:1449-1463.
46. Goodin DS, Arnason BG, Coyle PK, et al. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003;61:1332-1338.
47. Cohen JA, Barkhof F, Comi G, The TRANSFORMS Study Group. Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. N Engl J Med. 2010;362: P402-415.
48. Food and Drug Administraion Peripheral and Central Nervous System Drugs Advisory Committee. Briefng Materials. June 10, 2010. Available at: http://www.fda.gov/Advisory-Committees/CommitteesMeetingMaterials/Drugs/ PeripheralandCentralNervousSys-temDrugsAdvisoryCommittee/ucm216547. htm. Accessed July 29, 2010.
49. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416-426.
50. National Institutes of Health. ClinicalTrials. gov. Available at: http://clinicaltrials.gov/ct2/ results?term=fumarate&recr=&rslt= &type=&cond=multiple+sclerosis&intr=&outc=&lea d=&spons=&id=&state1 = &cntry1 = &state2 = &cntry2=&state3=&cntry3 = &locn=&gndr= &rcv-s=&rcv- e=&lup-s=&lup-e=. Accessed July 29, 2010.
51. Kappos L, Gold R, Miller DH, et al. Effcacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomized, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372:1463-1472.
52. Tallantyre E, Evangelou N, Constantinescue CS. Spotlight on teriflunomide. INtl MS J. 2008;15:62-68.
53. National Institutes of Health. ClinicalTrials. gov. Available at: http://clinicaltrials.gov/ct2/ results?term=teriflunomide+MS. Accessed July 29, 2010.
54. O'Connor PW, Li D, Freedman MS, et al. A phase II study of the safety and effcacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006;66:894-900.
55. Tselis A. Laquinimod, a new oral autoimmune modulator for the treatment of relaps-ing-remitting multiple sclerosis. Curr Opin Investig Drugs. 2010;11:577-585.
56. National Institutes of Health,. Clinical Trials. gov. Available at: http://clinicaltrials.gov/ct2/ results?term=Laquinimod&recr=&rslt= &ty pe=&cond=multiple+sclerosis&intr=&outc= &lead= &spons=&id=&state1 = &cntry1=&sta te2 = &cntry2 = &state3 = &cntry3 = &locn=&g ndr=&rcv-s=&rcv-e=&lup- s=&lup-e=. Accessed July 29, 2010.
57. National Institutes of Health. Clinical Trials. gov. Available at: http://clinicaltrials.gov/ct2/ results?term=alemtuzumab+MS. Accessed July 29, 2010.
58. The CAMMS223 Trial Investigators. Alem-tuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359:1786-1801.
59. Hauser SI, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676-688. (Pubitemid 351240747)
60. Nalsmith RT, Piccio L, Lyons JA, et al. Ritux-imab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology. 2010;74:1860-1867.
61. Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomized, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurology. 2010;9:381-390.
62. National Institutes of Health. ClinicalTrials. gov. Available at: http://clinicaltrials.gov/ct2/r esults?term=daclizumab+multiple+sclerosis. Accessed July 29, 2010.
63. Naci H, Fleurence R, Birt J, Duhig A. Economic burden of multiple sclerosis: a systematic review of literature. Pharmacoeconomics. 2010;28(5):363-379.
64. Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the frst-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm. 2009;15:543-555.
65. Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66:1696-1702. (Pubitemid 43964625)
66. Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm. 2007;13:245-261.